Understanding state restrictions on GLP-1s and peptides

The regulatory framework around research peptides and GLP-1 agonists shifts faster than most clinical practices can track. A drug class that was widely compounded in 2023 may be flatly prohibited in 2024 in some states, while in others it remains accessible only under a research authorization or an IRB-approved protocol. This guide explains how federal and state authority interact, why GLP-1s are under particular scrutiny, what the current state-by-state matrix looks like for the seven highest-volume jurisdictions in our customer base, how Purity Science enforces these rules at checkout, and what your exposure looks like if you operate outside the bounds.

Federal vs. state regulatory authority

The federal Food, Drug, and Cosmetic Act (FDCA) gives the FDA primary authority over interstate commerce in drugs. Two sections matter most for compounded peptide work:

• § 503A allows pharmacies to compound for an identified patient pursuant to a valid prescription, using bulk APIs that appear on the FDA's bulk substances list. The pharmacist must hold a state license and operate within their state's compounding rules.
• § 503B governs outsourcing facilities — large-scale compounders that must register with FDA and follow current good manufacturing practice (cGMP). 503B output can be shipped office-stock to clinicians without a patient-specific prescription.

State boards of pharmacy regulate the practice of pharmacy within their borders. They license pharmacists, inspect facilities, and enforce both federal compounding rules and any state-specific overlay. Where state law is more restrictive than federal law, state law controls within that state. Where federal law is more restrictive, federal law controls.

For peptides, the practical effect is: every shipment crosses two authorities — the FDA's federal compounding rules, and the receiving state's local pharmacy laws. A peptide that's compoundable in California under FDA rules may still be prohibited by the California Board of Pharmacy.

Why GLP-1s are under particular scrutiny

GLP-1 receptor agonists — semaglutide, tirzepatide, retatrutide, and related molecules — went from a niche diabetes treatment to a blockbuster weight-loss category in 2022-2024. Three things happened at once:

1. Shortage status. The FDA placed semaglutide and tirzepatide on the official drug shortage list, which under § 503A and § 503B opened the door to compounding. Practitioners who had never compounded peptides before began offering compounded GLP-1s.
2. Resolution of shortage. As of 2025-2026, both molecules have either been removed from the shortage list or are scheduled to be removed. When a molecule comes off the shortage list, the legal basis for compounding it from bulk API ends; compounding can continue only when a specific clinical reason justifies it for an identified patient.
3. State enforcement. State pharmacy boards, alarmed by the volume of off-label compounded GLP-1 distribution and a few high-profile adverse-event incidents, began issuing emergency rules tightening or prohibiting GLP-1 compounding within their states.

The result is a fragmented map where what's allowed depends on the specific molecule, the specific state, the specific date, and the specific clinical justification documented in the patient chart.

State-by-state matrix

The current state of restrictions in the seven highest-volume jurisdictions in our customer base, as of this guide's publication date. Always verify with your own counsel before acting; rules change frequently.

California. Compounded GLP-1s permitted under § 503A for an identified patient with a documented medical reason, provided the API is from an FDA-registered source. Office-stock distribution prohibited. CA Bus. & Prof. Code § 4127 and 16 CCR § 1735.

New York. Compounded GLP-1s restricted. Per recent NYS Board of Pharmacy guidance, compounded semaglutide and tirzepatide require a documented medical exception and a 503A-compliant prescription; office-stock office-use is prohibited. Research authorizations may be available through the State Department of Health for clinics participating in IRB-approved protocols.

Texas. Compounded GLP-1s permitted under § 503A with a patient-specific prescription. The Texas State Board of Pharmacy has not issued an emergency rule restricting compounded GLP-1s beyond the federal baseline as of the publication date.

Florida. Compounded GLP-1s permitted under § 503A. Florida Department of Health requires that compounded semaglutide be dispensed only when commercial product is unavailable to the specific patient, and the basis for unavailability must be documented in the chart.

Louisiana. Compounded GLP-1s currently restricted. The Louisiana Board of Pharmacy issued a 2024 emergency rule prohibiting compounded semaglutide from bulk API except for FDA-approved 503B outsourcing facilities. Practitioners in LA should source compounded GLP-1s only from registered 503B facilities and document the source on every dispensing record.

Mississippi. Compounded GLP-1s permitted under § 503A but the Mississippi Board of Pharmacy has issued advisory guidance recommending that all GLP-1 compounding cease unless the patient meets the FDA's clinical-need criteria documented at the time of dispensing.

Tennessee. Compounded GLP-1s permitted under § 503A. Tennessee Board of Pharmacy follows the federal baseline; no state-specific emergency rule has been issued.

The remaining 43 states + DC range from fully permissive to fully prohibited and are not enumerated here. If you operate in a state not listed above, consult the state pharmacy board's most recent guidance and the FDA's most recent compounding guidance jointly.

How Purity Science enforces these rules

Every SKU in our catalog carries a restricted_states array — a list of state codes where that SKU cannot ship at all. When you go through checkout:

1. The system identifies the shipping address on the order.
2. It compares the state of the shipping address against the restricted_states array on each line item.
3. If a match is found, checkout is blocked with an explicit message identifying which SKU is restricted and which state triggered the block.

For products with a compliance_flag = true, an additional disclaimer step appears at checkout: the practitioner must affirm that the order is being placed on behalf of a clinical or research operation operating within the bounds of state law before the order can complete.

For GLP-1 products specifically, the disclaimer text references the current state of the shortage list and the practitioner's individual responsibility to confirm compounding eligibility before ordering. The disclaimer text is versioned (see disclaimer_versions in our database) and your acceptance is logged against your account with a timestamp.

What to do if you operate under an exception

If your practice operates under a research authorization, an IRB-approved protocol, or a 503B outsourcing facility framework that overrides default state restrictions, Purity Science can configure an exception at the organization level.

Open a support ticket from your account dashboard. The exception request should include:

• The state(s) where the exception applies.
• The legal basis for the exception (statute, IRB number, 503B registration).
• A copy of the authorization or registration document.
• The specific SKUs the exception covers.

Our compliance team reviews these on a case-by-case basis. Once approved, the exception attaches to your organization and applies on every order placed by every member of your account. Exceptions expire on the authorization's expiration date — you're responsible for renewing the underlying authorization and notifying us with the renewed document.

Penalties for non-compliance

Penalties for compounding outside state authority depend on the state and the severity of the conduct. A representative range:

• Administrative: state board fines (typically $1,000–$25,000 per violation), license suspension, license revocation. State boards generally treat first offenses as warnings if the conduct is corrected; repeat offenses escalate quickly.
• Civil: malpractice exposure if a patient is harmed by a compounded product that violated state law. The malpractice carrier may decline coverage if the conduct was outside the bounds of your scope of practice.
• Criminal (rare but possible): the FDCA includes criminal penalties for knowingly distributing adulterated or misbranded drugs. State pharmacy practice acts often include similar provisions.

The single highest-risk pattern we observe is operating under the assumption that a federal allowance overrides a state prohibition. It does not. If your state prohibits a practice that federal law permits, the state prohibition controls within that state.

Recordkeeping for off-label use

When you dispense or administer a compounded peptide for an indication outside the FDA-approved label, several recordkeeping elements need to appear in the patient chart:

• The clinical reasoning for choosing the compounded product over a commercially available alternative.
• The documented unavailability of an FDA-approved equivalent at the time of dispensing.
• The patient's informed consent acknowledging the off-label status.
• The lot number, expiration date, and COA reference for the specific vial(s) administered.
• A follow-up plan that tracks clinical response and adverse events.

Auditors look for these elements in every chart. Missing any of them weakens both your regulatory defense and your malpractice defense.

FAQ

Q: Does Purity Science guarantee a SKU is legal for me to use? A: No. We enforce shipping-side restrictions on the SKUs and states we've documented, but the legal use of the product within your state and your scope of practice is your responsibility. The disclaimer step at checkout captures this acknowledgement.

Q: What if the GLP-1 shortage list changes mid-order? A: The disclaimer text and the restricted-states array are evaluated at the time of order placement. Subsequent changes do not retroactively invalidate the order, but they may affect your ability to place future orders.

Q: Can I place an order for an out-of-state colleague's clinic? A: No. Orders ship to the address on the order; the restricted-states check applies to that address. If you need to drop-ship to a colleague, place the order on their account.

Q: How do I request a state allowlist exception? A: Open a support ticket from your account dashboard, category "Compliance". Attach the supporting documentation (research authorization, IRB letter, 503B registration). Our compliance team responds within 5 business days.

Q: Are these state rules the same for all peptides? A: No — restrictions are SKU-specific. Most peptides are compoundable in most states; GLP-1s have the tightest restrictions because of their commercial profile and the FDA shortage history. BPC-157, CJC-1295, TB-500, and similar molecules generally face fewer state-specific restrictions.

Q: What's the difference between a 503A pharmacy and a 503B outsourcing facility? A: 503A pharmacies compound for identified patients pursuant to specific prescriptions. 503B facilities can compound office-stock without a patient-specific prescription but must follow cGMP and register with FDA. The legal pathways are distinct; conflating them is a common source of compliance error.

Q: If I'm operating under a research authorization, do I still need patient consent? A: The IRB protocol determines consent requirements. Most IRB-approved research protocols require informed consent that explicitly references the research nature of the work and the lack of FDA approval for the specific indication.

Q: How often does this matrix change? A: Frequently. We update this guide quarterly and email account owners when material changes occur in the states where they have shipping addresses on file.

For specific situations not addressed here, open a support ticket with category "Compliance" or email support@purityscience.com.